This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ISR Immune System Regulation Holding Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Belangrijke informatie
-57.2%
Groei van de winst
-28.7%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 0.7% |
| Inkomstengroei | 98.2% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | n/a |
| Laatste winstupdate | 31 Dec 2022 |
Recente prestatie-updates uit het verleden
Recent updates
We're Not Very Worried About ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Rate
Aug 11
A Look At The Fair Value Of ISR Immune System Regulation Holding AB (publ) (STO:ISR)
Jul 02Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Mar 08Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Nov 18Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Jul 27Here's Why We're Watching ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Situation
Mar 26We Think ISR Immune System Regulation Holding (STO:ISR) Can Afford To Drive Business Growth
Dec 11
Opbrengsten en kosten
Hoe ISR Immune System Regulation Holding geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -213 | 24 | 179 |
| 30 Sep 22 | 0 | -235 | 26 | 203 |
| 30 Jun 22 | 0 | -257 | 29 | 226 |
| 31 Mar 22 | 0 | -168 | 26 | 141 |
| 31 Dec 21 | 0 | -79 | 22 | 56 |
| 30 Sep 21 | 0 | -60 | 20 | 40 |
| 30 Jun 21 | 0 | -41 | 18 | 24 |
| 31 Mar 21 | 0 | -36 | 16 | 20 |
| 31 Dec 20 | 0 | -31 | 14 | 16 |
| 30 Sep 20 | 0 | -29 | 13 | 15 |
| 30 Jun 20 | 0 | -28 | 12 | 14 |
| 31 Mar 20 | 0 | -28 | 13 | 15 |
| 31 Dec 19 | 0 | -29 | 13 | 16 |
| 30 Sep 19 | 0 | -29 | 14 | 15 |
| 30 Jun 19 | 0 | -28 | 14 | 14 |
| 31 Mar 19 | 0 | -25 | 12 | 12 |
| 31 Dec 18 | 0 | -21 | 11 | 10 |
| 30 Sep 18 | 0 | -20 | 13 | 19 |
| 30 Jun 18 | 0 | -18 | 11 | 17 |
| 31 Mar 18 | 0 | -18 | 10 | 14 |
| 31 Dec 17 | 0 | -21 | 9 | 12 |
| 30 Sep 17 | 0 | -30 | 1 | 0 |
| 30 Jun 17 | 0 | -21 | 4 | 0 |
| 31 Mar 17 | 0 | -27 | 2 | 0 |
| 31 Dec 16 | 0 | -14 | 5 | 0 |
Kwaliteitswinsten: ISR is currently unprofitable.
Groeiende winstmarge: ISR is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: ISR is unprofitable, and losses have increased over the past 5 years at a rate of 57.2% per year.
Versnelling van de groei: Unable to compare ISR's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: ISR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.9%).
Rendement op eigen vermogen
Hoge ROE: ISR's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.